Stock events for Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines' stock has experienced significant volatility, with a 778.82% increase over the past year as of March 4, 2026. Key events include a 1-for-15 reverse stock split on November 29, 2023, Breakthrough Designation from the FDA for Ulixacaltamide, positive trial results for an epilepsy drug, NDA submissions for Ulixacaltamide and Relutrigine, Q4 2025 earnings reporting ($3.50) earnings per share, and Wolfe Research initiating coverage with an "Outperform" recommendation.
Demand Seasonality affecting Praxis Precision Medicines, Inc.’s stock price
There is no explicit information available regarding demand seasonality for Praxis Precision Medicines, Inc.'s products or services. Demand is likely driven by disease prevalence, unmet medical needs, clinical efficacy, regulatory approvals, and market access, rather than seasonal fluctuations.
Overview of Praxis Precision Medicines, Inc.’s business
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders by translating genetic insights into treatments for conditions characterized by neuronal excitation-inhibition imbalance. The company operates within the Healthcare sector, utilizing its Cerebrum and Solidus platforms to develop neurological disorder therapies. Praxis has a diversified CNS portfolio with clinical-stage product candidates targeting movement disorders and epilepsy, including Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen.
PRAX’s Geographic footprint
Praxis Precision Medicines, Inc. is headquartered in Boston, Massachusetts, United States, and its development activities for CNS disorders are conducted in the United States.
PRAX Corporate Image Assessment
Praxis Precision Medicines generally holds a positive brand reputation, with a consensus rating of "Moderate Buy" or "Buy" from analysts. The FDA's Breakthrough Designation for Ulixacaltamide, positive clinical trial results, and analyst confidence contribute to its strong reputation. While the company's stock has been volatile and it reported a wider net loss in Q4 2025, these financial aspects are more related to investor sentiment and financial performance rather than a direct impact on the scientific or ethical brand reputation.
Ownership
The ownership structure of Praxis Precision Medicines stock includes institutional investors (approximately 18.66% to 30.74%), insiders (approximately 18.01%), and public companies and individual/retail investors. Major institutional holders include Janus Henderson Group PLC, BlackRock, Inc., and Perceptive Advisors LLC. Bsof Parallel Master Fund LP is a significant individual shareholder. Steven A. Cohen is mentioned as owning the most shares of Praxis Precision Medicines.
